Novartis reported success for its BTK inhibitor remibrutinib (Rhapsido) in two large Phase 3 multiple sclerosis studies, describing superiority over Aubagio in reducing annualized relapse rates and inflammatory brain lesions. The company also said the treatment delivered clinically meaningful effects on disability progression and did not impact liver safety, a key issue in BTK inhibitor development. Novartis did not provide detailed study results in the disclosure, but the company intends to share the findings with regulators. Analysts and investors will focus on the full dataset, including safety monitoring and the robustness of efficacy across key MS subgroups. The results potentially expand remibrutinib’s commercial scope beyond its existing approval for chronic skin hives into MS, as Novartis seeks late-stage assets to offset patent expirations.